文献速递神经肿瘤

血浆IL13Rα2作为胶质母细胞瘤新型液体活检生物标志物

Plasma IL13Rα2 as a novel liquid biopsy biomarker for glioblastoma.
PubMed 文献 · J Neurooncol · 2022-11-27

研究比较原发胶质母细胞瘤患者与健康对照的血浆IL13Rα2水平,采用ELISA检测并经PEG沉淀富集细胞外囊泡优化。血浆IL13Rα2升高与肿瘤组织表达相关,且预测更长总生存期(19.8 vs 13.2个月);肿瘤组织IL13Rα2阳性细胞同样预测更长总生存期(22.1 vs 12.2个月)。作者认为该标志物可用于无创液体活检及靶向治疗患者筛选。

要点

  • 血浆IL13Rα2在胶质母细胞瘤患者中可检测,PEG沉淀富集细胞外囊泡可优化检测。
  • 血浆IL13Rα2升高与肿瘤组织表达相关,并预测更长总生存期(19.8 vs 13.2个月)。
  • 肿瘤组织IL13Rα2阳性细胞检测同样预测更长总生存期(22.1 vs 12.2个月)。

核心结论

  • 研究结果强烈提示IL13Rα2受体表达赋予胶质母细胞瘤患者生存优势,可通过微创液体活检确定。
  • 检测血浆IL13Rα2还可用于筛选适合靶向肿瘤治疗的胶质母细胞瘤患者。

研究设计与样本

  • 研究纳入来自Penn State和Cleveland Clinic的原发胶质母细胞瘤患者,并与健康对照比较。
  • 采用ELISA检测血浆IL13Rα2,并可通过PEG沉淀富集细胞外囊泡优化检测。

主要发现

  • 胶质母细胞瘤患者血浆IL13Rα2水平升高,且与肿瘤组织中该受体水平相关。
  • 血浆IL13Rα2升高预测更长总生存期(19.8 vs 13.2个月)。
  • 肿瘤组织检测到IL13Rα2阳性细胞同样预测更长总生存期(22.1 vs 12.2个月)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Glioblastoma (GBM) is the most common and deadliest brain tumor with unrelenting and rapid disease progression. The standard of care for GBM is surgical excision followed by radiation with concurrent and adjuvant temozolomide-centered chemotherapy (TMZ). Treatment failure and resistance is the rule and despite advances in imaging technology, early detection of treatment failure or impending resistance remains a challenge. There is a dire, unmet, need in clinical practice for minimally-invasive diagnostic tools to enable timely understanding of disease progression and treatment response. Here, we aim to address this clinical need by leveraging a unique characteristic of GBM: the overexpression of the α2 variant of the IL-13 receptor in over 75% of GBM tumors. METHODS: In this study we examined patients with primary GBM from Penn State and Cleveland Clinic compared to healthy controls. RESULTS: IL13Rα2 was detectable in plasma of GBM patients using ELISA but detection could be optimized by PEG precipitation to enrich for extracellular vesicles (EVs). Patients with GBM had elevated levels of plasma IL13Rα2, which correlated to levels of this receptor in the tumor tissue. Elevated plasma levels of IL13Rα2 predicted longer overall survival (OS) (19.8 vs. 13.2 months). Similarly, detection of IL13Rα2 + cells in tumor tissue also predicted longer OS (22.1 vs. 12.2 months). CONCLUSION: These findings strongly suggest that expression of the IL13Rα2 receptor confer survival advantage in GBM patients, which can be determined through a minimally-invasive liquid biopsy. Detection of plasma IL13Rα2 can also be used to select GBM patients for targeted tumor therapy.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Khristov V, Nesterova D, Trifoi M, et al. Plasma IL13Rα2 as a novel liquid biopsy biomarker for glioblastoma. J Neurooncol. 2022. PMID: 36436150. doi:10.1007/s11060-022-04196-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。